Underweight and overweight: between Scylla and Charybdis
https://doi.org/10.18705/1607-419X-2009-15-6-633-639
Abstract
It is well known that overweight as well as underweight is strongly associated with increased risk of development of many disorders, particularly cardiovascular pathology. The paper discloses the most appreciable problems of health associated with obesity and underweight. Pathophysiological mechanisms of development of the basic metabolic disturbances underlying obesity and diabetes mellitus, such as insulin resistance and dyslipoproteinemia, are described. The interaction of hereditary and environmental factors leading to adiposity is discussed in the light of the novel theories of development of adiposity, such as the hypothesis of a thrifty phenotype and "the selfish brain theory". Particular cases of obesity development in the absence of insulin resistance are described. The clinical phenomenon of paradoxical more favorable prognosis in patients with overweight in comparison with patients with normal weight and underweight (the obesity paradox) is discussed.
About the Authors
O. M. Drapkina
I.M. Sechenov Moscow Medical Academy
Russian Federation
Russian Federation
O. N. Dikur
The V.H.Vasilenko Clinic of Internal Diseases Propedeutics, Gastroenterology and Hepatology
Russian Federation
Russian Federation
References
1. История красоты / Под ред. Эко У. - Перевод с итал. - М.: СЛОВО/SLOVO, 2005. - 440 с.
2.
3. Винкельман И.И. История искусства древности. Малые сочинения. - СПб.: Алетейя, Государственный Эрмитаж, 2000. - 800 с
4.
5. World Health Organization: Obesity: preventing and managing the global epidemic, Report of a WHO Consultation on Obesity. Geneva, World Health Organization, 1998.
6.
7. Haile M. Weather patterns, food security and humanitarian response in sub-Saharan Africa // Philos. Trans. R. Soc. Lond. B. Biol. Sci. - 2005. - Vol. 360, № 1463. - P. 2169-2182.
8.
9. Vass A. Famine relief must also tackle health care // Br. Med. J. - 2002. - Vol. 325, № 7360. - P. 355.
10.
11. Fitzpatrick A.L., Kuller L.H., Lopez O.L. et al. Midlife and late-life obesity and the risk of dementia // Arch. Neurol. - 2009. - Vol. 66, № 3. - P. 336-342.
12.
13. Kronenberg H.M., Melmed S., Polonsky K.S., Larsen P.R. Williams textbook of endocrinology. - 11th ed. - USA, PA, Philadelphia.: Saunders Elsevier, 2008. - 1914 p.
14.
15. Ritchie S.A., Ewart M.A., Perry C.G. et al. The role of insulin and adipocytokines in regulation of vascular endothelial function // Clin. Sci. - 2004. - Vol. 107, № 6. - P. 519-532.
16.
17. Bloomgarden Z.T. Inflammation, atherosclerosis, and aspect of insulin action // Diabetes Care. - 2005. - Vol. 28, № 9. - P. 2312-2319.
18.
19. Reaven G.M. Insulin resistance, the insulin resistance syndrome, and cardiovascular disease // Panminerva Medica. - 2005. - Vol. 47. - P. 201-210.
20.
21. Bains R.K, Wells S.E., Flavell D.M. Visceral obesity without insulin resistance in late-onset obesity rats. Endocrinology. - 2004 - Vol. 145, № 6. - P. 2666-2679.
22.
23. Franckhauser S. Muñoz S., Pujol A. et al. Increased fatty acid re-esterification by PEPCK overexpression in adipose tissue leads to obesity without insulin resistance // Diabetes. - 2002. - Vol. 51, № 3. - P. 624-630.
24.
25. Fisher M., McMurray J.J. Diabetic cardiology. - England, West Sussex, Chichester: John Wiley & Sons, Ltd, The Atrium, Southern Gate, 2007. - 295 p.
26.
27. Freeman D.R., Norrie J., Caslake M.J. et al. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study // Diabetes. - 2002. - Vol. 51, № 5. - P. 1596-1600.
28.
29. Ederly L.E., Stamler J., Neaton J.D. Relation of triglyceride levels, fasting and nonfasting, to fatal and nonfatal coronary heart disease // Arch. Intern. Med. - 2003. - Vol. 163, № 9. - P. 1077-1083.
30.
31. Walldius G., Jungner I., Holme I., Aastveit A.H. High apolipoprotein B, low apolipoprotein A-I, and improvement in the predictor of fatal myocardial infarction (AMORIS study): a prospective study // Lancet. - 2001. - Vol. 358, № 9298. - P. 2026-33.
32.
33. Sniderman A.D. Applying apoB to the diagnosis and therapy of the atherogenic dyslipoproteinemias: a clinical diagnostic algorithm // Curr. Opin. Lipidol. - 2004. - Vol. 15, № 4. - P. 433-438.
34.
35. Haler C.N., Barker D.J. Type 2 (non-insulin-dependent) diabetes mellitus: the thrifty phenotype hypothesis // Diabetologia. - 1992. - Vol. 35, № 7. - P. 595-601.
36.
37. Pratley R.E. Gene-environment interactions in the pathogenesis of type 2 diabetes mellitus: lessons learned from the Pima Indians // Proc. Nutr. Soc. - 1998. - Vol. 57, № 2. - P. 175-181.
38.
39. Peters A., Schweiger U., Pellerin L. et al. The selfish brain: competition for energy resources // Neurosci. Biobehav. Rev. - 2004. - Vol. 28, Issue 2 - P. 143-180.
40.
41. Kalsbeek A., Fliers E., Hofman M.A. et al. Hypothalamic integration of energy metabolism: proceedings of the 24th International Summer School of Brain Research. - The Netherlands, Amsterdam: Elsevier, 2006. - 413 p.
42.
43. Curtis J.P., Selter J.G., Wang Y., Rathore S.S. The obesity paradox: body mass index and outcomes in patients with heart failure // Arch. Intern. Med. - 2005. - Vol. 165, № 1. - P. 55-61.
44.
45. Moser D.K., Lennie T.A., Riegel B., McKinley Sh. Abstract 4604: Prediction of mortality by body mass index: evidence that the obesity paradox extends to patients with stable coronary heart disease: Am Heart Assoc. Abstracts book // Circulation. - 2008. - Vol. 118. - P. S919-S920.
46.
47. Gruberg L., Weissman N.J., Waksman R. et al. The impact of obesity on the short-term and long-term outcomes after percutaneous coronary intervention: the obesity paradox? // J. Am. Coll. Cardiol. - 2002. - Vol. 39, № 4. - P. 578-584.
48.
49. Tankó L.B., Christiansen C. Can the obesity paradox be explained by the protective effects of peripheral adiposity? // Arch. Intern. Med. - 2005. - Vol. 165, № 15. - P. 1796-1797
50.
51. The practical guide: identification, evaluation, and treatment of overweight and obesity in adults. - 2000. - Issues 0-4084 of NIH publication. - P. 895.
52.
53. Hansen D., Astrup A., Toubro S. et al. for The STORM study group M. Predictors of weight loss and maintenance during 2 years of treatment by sibutramine in obesity. Results from the European multi-centre STORM trial. Sibutramine trial of obesity reduction and maintenance // Int. J. Obes. Relat. Metab. Disord. - 2001. - Vol. 25, № 4. - P. 496-501.
54.
55. Padwal R.S., Majumdar S.R . Drug treatments for obesity: orlistat, sibutramine, and rimonabant // Lancet. - 2007. - Vol. 369, № 9555. - P. 71-77.
56.
Review
For citations:
Drapkina O.M., Dikur O.N. Underweight and overweight: between Scylla and Charybdis. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2009;15(6):633-639. (In Russ.) https://doi.org/10.18705/1607-419X-2009-15-6-633-639
Views:
914
Email this article 